SLU-PP-332 Tablets

SLU-PP-332 is a synthetic pan-ERR agonist studied in non-human research models in relation to estrogen-related receptor (ERRα, ERRβ, ERRγ) activation, mitochondrial biogenesis signaling, and oxidative phosphorylation pathway behavior. Scientific literature examines this compound in the context of nuclear receptor-mediated gene expression regulation, PGC-1α co-activator pathway activity, and skeletal muscle metabolic signaling in controlled non-human laboratory environments.

Research applications commonly explored in the literature include:

ERRα, ERRβ, and ERRγ receptor subtype agonism and downstream signaling pathway investigation in non-human models

Mitochondrial biogenesis signaling and oxidative phosphorylation pathway research

PGC-1α co-activator pathway activity and nuclear receptor-mediated gene expression regulation

Skeletal muscle metabolic signaling and fiber-type pathway modeling in non-human research frameworks

Comparative pan-ERR agonist selectivity and receptor subtype activation studies in controlled laboratory settings

The tablet format supports consistent compound delivery across experimental preparations, allowing researchers to evaluate nuclear receptor agonism parameters and downstream pathway responses within controlled non-human research protocols. Each SLU-PP-332 tablet from KÖLD is manufactured under controlled laboratory conditions. All batches are verified by independent third-party laboratories for purity, tablet weight accuracy, and molecular identity.

1. What is SLU-PP-332 studied for in research settings?
   SLU-PP-332 appears in scientific literature as a pan-ERR agonist studied in non-human models in relation to estrogen-related receptor activation, mitochondrial biogenesis signaling, and oxidative metabolism pathway regulation. Research investigates how ERR subtype activation influences downstream PGC-1α pathway activity and mitochondrial function in non-human systems.
2. What are estrogen-related receptors (ERRs) and why are they studied as research targets?
   Estrogen-related receptors (ERRα, ERRβ, ERRγ) are nuclear receptors involved in regulating mitochondrial biogenesis, oxidative phosphorylation, and metabolic gene expression. Despite their name, ERRs are structurally distinct from classical estrogen receptors and do not respond to estrogen. Scientific literature examines ERRs as metabolic research targets due to their role in cellular energy regulation and mitochondrial pathway dynamics in non-human models.
3. Why is SLU-PP-332 supplied in tablet format?
   The tablet format supports consistent compound handling and preparation across experimental protocols, allowing researchers to evaluate nuclear receptor agonism and downstream metabolic pathway responses within controlled non-human research settings without requiring reconstitution procedures.
4. Is SLU-PP-332 approved for any use in humans or animals?
   No. SLU-PP-332 is not approved for human or veterinary use. All products sold by KÖLD are strictly for in vitro and non-human laboratory research purposes only.
5. How is purity and quality verified?
   Each batch of SLU-PP-332 tablets undergoes independent third-party laboratory testing to confirm molecular identity, purity, and tablet weight accuracy prior to release.

Store tablets in a cool, dry place between 15–25°C (59–77°F)

Keep away from direct sunlight, heat, and moisture

Do not refrigerate or freeze

Reconstitution is not required.
This product is supplied in tablet format.
For research use only. Not for human or animal use.
Not intended to diagnose, treat, cure, or prevent any disease.